Esperion Therapeutics
Last update: 2:02PM
15 minutes delayed
Day High/Low6.13 - 6.37
52 Week High/Low3.28 - 21.68
Open / Close6.3 / -
Float / Outstanding44.4M / 63M
Vol / Avg.418.3K / 1.2M
Mkt Cap396.3M
50d Avg. Price5.74
Div / Yield-
Payout Ratio-
Total Float44.4M

Esperion Therapeutics (NASDAQ:ESPR), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1


Highest Price Target1


Lowest Price Target1


Consensus Price Target1


Analyst Rating Summary1


Analyst Firms Making Recommendations1

  • Goldman Sachs
  • JP Morgan
  • HC Wainwright & Co.
  • Credit Suisse

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for Esperion Therapeutics

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

Esperion Therapeutics Questions & Answers

What is the target price for Esperion Therapeutics (ESPR)?

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Goldman Sachs on May 24, 2022. The analyst firm set a price target for $3.00 expecting ESPR to fall to within 12 months (a possible -52.31% downside). 11 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Esperion Therapeutics (ESPR)?

The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Goldman Sachs, and Esperion Therapeutics maintained their sell rating.

When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on May 24, 2022 so you should expect the next rating to be made available sometime around May 24, 2023.

Is the Analyst Rating Esperion Therapeutics (ESPR) correct?

While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a maintained with a price target of $3.50 to $3.00. The current price Esperion Therapeutics (ESPR) is trading at is $6.29, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.